Efek pemberian beberapa jenis antikoagulan sebagai profilaksis sindrom pasca trombotik setelah DVT (systematic literature review)
DOI:
https://doi.org/10.55606/jikki.v5i2.6836Keywords:
deep vein thrombosis, anticoagulants, post-thrombotic syndrome, VKA, LMWHAbstract
This study aimed to evaluate the efficacy of several types of anticoagulants—VKA, LMWH, and DOAC in preventing PTS after DVT through a systematic literature review. The method used involved secondary data search from databases such as PubMed, ScienceDirect, and Google Scholar between 2013–2024, with inclusion criteria including randomized clinical trials and related observational studies. The results showed that DOAC, especially rivaroxaban, significantly reduced the incidence and severity of PTS compared to VKA, with a lower risk of severe PTS. LMWH also showed positive results, although head-to-head evidence with DOAC is still limited. These findings suggest that the type and duration of anticoagulant therapy play an important role in preventing PTS, and encourage the need for further research, especially RCTs between LMWH and DOAC.
References
Alquwaizani, M., Buckley, L., Adams, C., & Fanikos, J. (2013). Anticoagulants: A review of the pharmacology, dosing, and complications. Current Emergency and Hospital Medicine Reports, 1, 83–97. https://doi.org/10.1007/s40138-013-0014-6
Aryana, S., Astika, N., & Kuswardhani, T. (2018). Geriatric Opinion 2018. Geriatric Opinion, December, 11.
Berkner, K. L., & Runge, K. W. (2022). Vitamin K-dependent protein activation: Normal gamma-glutamyl carboxylation and disruption in disease. International Journal of Molecular Sciences, 23(10), 5759. https://doi.org/10.3390/ijms23105759
Brown, C., Tokessy, L., Delluc, A., & Carrier, M. (2024). Risk of developing post-thrombotic syndrome after deep vein thrombosis with different anticoagulant regimens: A systematic review and pooled analysis. Thrombosis Research, 234, 109057. https://doi.org/10.1016/j.thromres.2024.109057
Chitsike, R. S., Rodger, M. A., Kovacs, M. J., Betancourt, M. T., Wells, P. S., Anderson, D. R., ... & Kahn, S. R. (2012). Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: Results from the REVERSE study. Journal of Thrombosis and Haemostasis, 10(10), 2039–2044. https://doi.org/10.1111/j.1538-7836.2012.04869.x
Couturaud, F., Pernod, G., Presles, E., Duhamel, E., Jego, P., Provost, K., ... & Mottier, D. (2019). Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis: The PADIS-DVT randomized clinical trial. Haematologica, 104(7), 1493–1501. https://doi.org/10.3324/haematol.2018.211177
Gwozdz, A. M., Black, S. A., Hunt, B. J., & Lim, C. S. (2020). Post-thrombotic syndrome: Preventative and risk reduction strategies following deep vein thrombosis. Vascular and Endovascular Review, 3, e15. https://doi.org/10.15420/ver.2020.22
Hull, R. D., Lip, G. Y., & Leung, L. (2017). Venous thromboembolism: Anticoagulation after initial management. In L. L. K. Leung & J. Mandel (Eds.), UpToDate. https://www.uptodate.com
Kaatz, S., Qureshi, W., Fain, C., & Paje, D. (2010). Duration of anticoagulation treatment in patients with venous thromboembolism. Journal of Osteopathic Medicine, 110(11), 638–644. https://jaoa.org/article.aspx?articleid=2094454
Karathanos, C., Nana, P., Spanos, K., Kouvelos, G., Brotis, A., Matsagas, M., & Giannoukas, A. (2021). Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: A systematic review and meta-analysis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 9(6), 1568–1576. https://doi.org/10.1016/j.jvsv.2021.02.002
Makedonov, I., Kahn, S. R., Abdulrehman, J., Schulman, S., Delluc, A., Gross, P., & Galanaud, J. P. (2022). Prevention of the postthrombotic syndrome with anticoagulation: A narrative review. Thrombosis and Haemostasis, 122(8), 1255–1264. https://doi.org/10.1055/a-1867-2349
Malik, A., Ha, N. B., & Barnes, G. D. (2024). Choice and duration of anticoagulation for venous thromboembolism. Journal of Clinical Medicine, 13(1), 301. https://doi.org/10.3390/jcm13010301
Prandoni, P. (2012). Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. European Journal of Haematology, 88(3), 185–194. https://doi.org/10.1111/j.1600-0609.2011.01744.x
Prandoni, P., Ageno, W., Ciammaichella, M., Mumoli, N., Zanatta, N., Imberti, D., ... & DOAC-PTS Investigators. (2020). The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants. Internal and Emergency Medicine, 15(3), 447–452. https://doi.org/10.1007/s11739-019-02142-7
Ray, I. (2019). A comparison of the efficacy and safety of acenocoumarol and warfarin in valve replaced patients with rheumatic heart disease (Doctoral dissertation, Rajiv Gandhi University of Health Sciences).
Schwarb, H., & Tsakiris, D. A. (2016). New direct oral anticoagulants (DOAC) and their use today. Dentistry Journal, 4(1), 5. https://doi.org/10.3390/dj4010005
Shao, J., Zhou, Q., Jin, F., Reissfelder, C., Sigl, M., Yagublu, V., & Keese, M. (2023). A systematic review and Bayesian network meta-analysis on the effect of different anticoagulants on the prophylaxis of post-thrombotic syndrome after deep venous thrombosis. Journal of Clinical Medicine, 12(23), 7450. https://doi.org/10.3390/jcm12237450
Søgaard, M., Nielsen, P. B., Skjøth, F., Kjældgaard, J. N., Coleman, C. I., & Larsen, T. B. (2018). Rivaroxaban versus warfarin and risk of post-thrombotic syndrome among patients with venous thromboembolism. The American Journal of Medicine, 131(7), 787–794. https://doi.org/10.1016/j.amjmed.2018.02.013
Sun, C., Zhao, W., Wang, X., Sun, Y., & Chen, X. (2020). A pharmacological review of dicoumarol: An old natural anticoagulant agent. Pharmacological Research, 160, 105193. https://doi.org/10.1016/j.phrs.2020.105193
Tenpas, A. S., Panahi, L., Udeani, G., Braaten, B., Ogbodo, C., De La Fuente, A., ... & Falade, O. (2024). Anticoagulation: Past, present, and future therapies. In Anticoagulation—An Update. IntechOpen. https://doi.org/10.5772/intechopen.114521
Van der Linden, L., Vanassche, T., Van Cutsem, E., Van Aelst, L., & Verhamme, P. (2023). Pharmacokinetic drug–drug interactions with direct anticoagulants in the management of cancer-associated thrombosis. British Journal of Clinical Pharmacology, 89(8), 2369–2376. https://doi.org/10.1111/bcp.15680
Wang, W., Su, Y., Wu, C., Sun, Y., Dai, N., Chen, W., ... & Li, J. (2020). Optimal duration of vitamin K antagonists anticoagulant therapy after venous thromboembolism: A systematic review and network meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, 20, 391. https://doi.org/10.1186/s12872-020-01732-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Jurnal Ilmu Kedokteran dan Kesehatan Indonesia
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
